Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 75 results for pulmonary embolism

  1. Direct oral anticoagulants for people with lower limb immobilisation:- What is the clinical and cost effectiveness of direct oral anticoagulants for preventing VTE in people with lower limb immobilisation?

    16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other

    Research recommendation
    Published
    15 November 2018

  2. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at moderately increased risk

    clot such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 9-11 for more information and...

  3. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at high risk

    clot such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 9-11 for more information and...

  4. Dose strategies for people who are obese:- What is the clinical and cost effectiveness of weight-based dose-adjustment strategies of lowmolecular-weight heparin (LMWH) compared with fixed-dose strategies of LMWH for preventing VTE in people who are very obese (BMI over 35) who are admitted to hospital or having day procedures (including surgery and chemotherapy)?

    16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other

    Research recommendation
    Published
    15 November 2018

  5. Risk assessment:- What is the accuracy of individual risk assessment tools in predicting the risk of venousthromboembolism (VTE) and risk of bleeding in people admitted to hospital?

    16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other

    Research recommendation
    Published
    15 November 2018

  6. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

    Evidence summary
    Published
    24 May 2016

  7. WoundExpress to manage lower leg wounds (MIB261)

    NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .

    Medtech innovation briefing
    Published
    1 June 2021

  8. Artificial intelligence for analysing chest CT images (MIB243)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .

    Medtech innovation briefing
    Published
    5 January 2021

  9. Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

    Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.

    Technology appraisal guidance
    Last updated
    1 December 2012
    View recommendations

    Sections for TA197

  10. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at high risk

    clot such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 14-17 for more information and...

  11. 500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause

    A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable.

    News
    Last updated
    27 March 2026

  12. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (IPG524)

    We have moved interventional procedures guidance 524 to become HealthTech guidance 376. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  13. AcQMap for mapping the heart atria to target ablation treatment for arrhythmias (MIB246)

    NICE has developed a medtech innovation briefing (MIB) on AcQMap for mapping the heart atria to target ablation treatment for arrhythmias .

    Medtech innovation briefing
    Published
    26 January 2021

  14. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at moderately increased risk

    clot such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 14-17 for more information and...

  15. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

    Evidence summary
    Published
    10 February 2015